| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/14/2001 | CN1284064A 2,3-substituted indole compounds as cox-2 inhibitors |
| 02/14/2001 | CN1284063A Compounds |
| 02/14/2001 | CN1284058A Neuroprotective agents |
| 02/14/2001 | CN1283990A Long cating injectable formulations contg. hydrogenated castor oil |
| 02/14/2001 | CN1283623A 1,2,4,5-tetrahydro-benzo[d] azepine compound |
| 02/14/2001 | CN1283506A Health-care composition and its preparing process |
| 02/14/2001 | CN1283497A Oral liquid for treating cerebrovascular disease and its preparing process |
| 02/14/2001 | CN1283479A Chinese medicine for treating puerperal puzzle diseases |
| 02/14/2001 | CN1283457A Medicine for treating hircus |
| 02/14/2001 | CN1061977C Aryl substituted heterocycles |
| 02/14/2001 | CN1061864C 消鼾口服液 Eliminate snoring oral |
| 02/14/2001 | CN1061862C Travelling instant powder |
| 02/14/2001 | CN1061849C Prodn process of medicated royal jelly |
| 02/13/2001 | US6187817 Preventing or reducing ototoxicity in a human, cat or dog by administering d-methionine free of the l-isomer |
| 02/13/2001 | US6187814 By topically an farnesoid x-activated receptor (fxr) activator selected from farnesal, alkyl farnesyl ether, alkyl farnesoate, and 7-methyl-9-(3,3-dimethyloxiranyl)-3-methyl-2,6-nonadienoic acid, alkyl ester |
| 02/13/2001 | US6187809 Beta-3 adrenaline receptor agonist drugs for the treatment of diabetes, obesity, and hyperlipemia; 2-(n-(2-(dibenzofuran-3-yloxy)ethyl)amino)-1-phenylethanol, for example |
| 02/13/2001 | US6187803 Treating allergic disease, autoimmune disease, immunodeficiency syndrome, inflammatory disease or eosinophilia by orally administering a histamine-added immunoglobulin and carrier; tablets, capsules |
| 02/13/2001 | US6187802 Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use |
| 02/13/2001 | US6187798 Heterocyclic compounds |
| 02/13/2001 | US6187795 Methods and compositions for treating allergic disorders and other disorders using norastemizole in combination with other active ingredients |
| 02/13/2001 | US6187794 Administering as antiasthmatic agent; side effect reduction |
| 02/13/2001 | US6187793 Psychosis, schizophrenia; antiallergens |
| 02/13/2001 | US6187791 Method of providing an antihistaminic effect in a hepatically impaired patient |
| 02/13/2001 | US6187777 Pyrrolo(3,2-d)pyrimidine derivatives; neuropeptide y and corticotropin releasing factor modulators; dietetics; antidiabetic, antiinflammatory, and antitumor agents |
| 02/13/2001 | US6187772 Pyrroloazepine compounds |
| 02/13/2001 | US6187767 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| 02/13/2001 | US6187751 Biologically active peptide of ob protein |
| 02/13/2001 | US6187742 Method for healing and repair of connective tissue attachment |
| 02/13/2001 | US6187586 Nucleotide sequence of compound which inhibits expression of human serine/threonine kinase involved in signal transduction; diagnosis, prophylaxis, and therapy of related diseases |
| 02/13/2001 | US6187562 Polynucleotides encoding human sphingosine Lyase |
| 02/13/2001 | US6187339 Solid pharmaceutical composition comprising an excipient capable of binding water |
| 02/13/2001 | US6187304 Effects of IFN-γ on cardiac hypertrophy |
| 02/13/2001 | CA2189830C Uses for corticotropin releasing factor atagonists |
| 02/13/2001 | CA2170065C Amide-derived bi-aromatic compounds; pharmaceutical and cosmetic compositions containing the same and their uses |
| 02/13/2001 | CA2147808C Acetylenic biaromatic compounds containing an adamantyl group; pharmaceutical and cosmetic compositions containing them and uses thereof |
| 02/13/2001 | CA2147806C Polyenic compounds; pharmaceutical and cosmetic compositions containing them and uses |
| 02/13/2001 | CA2012045C Pharmaceutical compositions containing 5'-deoxy-5'- methylthioadenosine, s-adenosylmethionine and their salts for hair growth in subjects suffering baldness |
| 02/12/2001 | CA2280249A1 Vanadium compounds as anti-angiogenics and as inhibitors of endothelin production |
| 02/10/2001 | WO2001032871A2 Follistatin-related protein zfsta4 |
| 02/10/2001 | CA2389956A1 Follistatin-related protein zfsta4 |
| 02/08/2001 | WO2001055118A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient |
| 02/08/2001 | WO2001009379A1 Antisense modulation of pepck-mitochondrial expression |
| 02/08/2001 | WO2001009346A1 Gene encoding novel adenylate kinase 3 (ak3)-like protein |
| 02/08/2001 | WO2001009325A2 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
| 02/08/2001 | WO2001009320A1 Gene encoding novel adp-ribosylation factor (arf)-like protein |
| 02/08/2001 | WO2001009307A2 Screen for nitric oxide synthase modulators |
| 02/08/2001 | WO2001009183A2 Polymorphisms in the human mdr-1 gene and applications thereof |
| 02/08/2001 | WO2001009173A2 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands |
| 02/08/2001 | WO2001009170A1 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (app) |
| 02/08/2001 | WO2001009160A1 Nucleic acid ligands to cd40ligand |
| 02/08/2001 | WO2001009156A1 HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS |
| 02/08/2001 | WO2001009146A1 Radiolabelled bisphosphonates and method |
| 02/08/2001 | WO2001009142A1 Oxazinocarbazoles for the treatment of cns diseases |
| 02/08/2001 | WO2001009139A1 Aromatic esters of camptothecins and methods to treat cancers |
| 02/08/2001 | WO2001009138A2 Chemokine receptor antagonists and methods of use therefor |
| 02/08/2001 | WO2001009134A1 Purine derivatives inhibitors of tyrosine protein kinase syk |
| 02/08/2001 | WO2001009132A1 C-6 RING-SUBSTITUTED PYRIDO[1,2-a]BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS |
| 02/08/2001 | WO2001009123A1 Benzofurylpiperazine serotonin agonists |
| 02/08/2001 | WO2001009122A2 Serotonergic benzofurans |
| 02/08/2001 | WO2001009121A2 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 02/08/2001 | WO2001009120A1 Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| 02/08/2001 | WO2001009116A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 02/08/2001 | WO2001009113A2 Heterocyclic compounds inhibiting angiogenesis |
| 02/08/2001 | WO2001009111A1 Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
| 02/08/2001 | WO2001009110A1 Novel succinate derivative compounds useful as cysteine protease inhibitors |
| 02/08/2001 | WO2001009106A1 Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors |
| 02/08/2001 | WO2001009103A2 Imidazole antiproliferative agents |
| 02/08/2001 | WO2001009097A1 Cyclic amine derivatives for the treatment of neurological diseases |
| 02/08/2001 | WO2001009093A1 Benzenamine derivatives as anti-coagulants |
| 02/08/2001 | WO2001009088A1 Urea derivatives as inhibitors of ccr-3 receptor |
| 02/08/2001 | WO2001009076A2 Retinoids for the treatment of emphysema |
| 02/08/2001 | WO2001008714A1 Cartilage or bone matrix as a nucleic acid delivery vehicle |
| 02/08/2001 | WO2001008708A2 Enhanced delivery via serpin enzyme complex receptor ligands |
| 02/08/2001 | WO2001008707A2 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 02/08/2001 | WO2001008699A1 Methods of inhibiting osteoclastogenesis |
| 02/08/2001 | WO2001008698A1 Activity potentiators for chemotherapeutics, anticancer compositions and method for potentiating the activity of chemotherapeutics |
| 02/08/2001 | WO2001008692A1 Xenon an nmda antagonist |
| 02/08/2001 | WO2001008690A1 Insertion stabilizers for implants |
| 02/08/2001 | WO2001008689A1 Ophthalmic compositions containing antibiotics and nsaids |
| 02/08/2001 | WO2001008685A1 Acyclic and cyclic amine derivatives |
| 02/08/2001 | WO2001008684A1 Nicotine in therapeutic angiogenesis and vasculogenesis |
| 02/08/2001 | WO2001008679A1 A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces |
| 02/08/2001 | WO2001008677A1 Methods of inhibiting osteoclast activity |
| 02/08/2001 | WO2001008670A2 Methods and compositions for alleviating stuttering |
| 02/08/2001 | WO2001008668A2 Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders |
| 02/08/2001 | WO2001008663A2 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 02/08/2001 | WO2001008635A2 Calcium channel transport polynucleotides, polypeptides, and antibodies |
| 02/08/2001 | WO2001008634A2 Polynucleotide encoding a human serine protease |
| 02/08/2001 | WO2000076984A3 Novel compounds, their use and preparation |
| 02/08/2001 | WO2000070017A3 Methods using of fab i and compounds modulating fab i activity |
| 02/08/2001 | WO2000069855A3 Furanone derivatives as inhibitors of cathepsin s |
| 02/08/2001 | WO2000068261A3 Attenuated microorganisms for the treatment of infection |
| 02/08/2001 | WO2000067798A3 Enhanced delivery of nucleic acid-based drugs |
| 02/08/2001 | WO2000067769A8 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents |
| 02/08/2001 | WO2000066141A3 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 02/08/2001 | WO2000064485A8 Specifically targeted catalytic antagonists and uses thereof |
| 02/08/2001 | WO2000063230A3 49 human secreted proteins |
| 02/08/2001 | WO2000061783A3 Process for preparing inhibitors of nucleoside metabolism |
| 02/08/2001 | WO2000059851A8 Derivatives of venlafaxine and methods of preparing and using the same |
| 02/08/2001 | WO2000059525A3 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES |